Travelling activity and travel-related risks after allogeneic haematopoietic stem cell transplantation - a single centre survey. Swiss Med Wkly. 2015;145:w14136..
Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Leuk Res. 2016;47:22-25..
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer Genomics Proteomics. 2016;13(5):317-329..
Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. Am J Hematol. 2018.
Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation: A Swiss Transplant Cohort Study. Transpl Infect Dis. 2018:e12981.
What the internist should know about stem cell transplant in the elderly patient. Eur J Intern Med. 2018..
Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days. Transfusion. 2019.
Dissociations of oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation. PLoS One. 2019;14(12):e0225099..
Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2019.
Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. Swiss Med Wkly. 2019;149:w20150..
Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.